BioSpace News Archive

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced several new customers have adopted the evo cold chain management system in clinical trials targeting cancer and other leading causes of death.

Oncoheroes Biosciences Inc. (“Oncoheroes”) and Boehringer Ingelheim International GmbH (“Boehringer Ingelheim”) have signed a worldwide, exclusive licensing agreement for volasertib, an investigational anti-cancer compound that was originally discovered and developed by Boehringer Ingelheim

Bayer today announced Daniella Foster as the new Head of Public Affairs and Sustainability for the Consumer Health Division, effective September 16.

Benitec Biopharma (ASX: BLT, NASDAQ: BNTC), today announced their plans to complete three non-clinical studies that will facilitate the filing of an Investigational New Drug (IND) application and the formal initiation of a Phase I clinical trial in patients suffering from Oculopharyngeal Muscular Dystrophy (OPMD).

Harmony Biosciences, LLC (Harmony) announced today it will present clinical data on the efficacy and safety of WAKIX® (pitolisant) at the World Sleep 2019 meeting in Vancouver, Canada from September 20-25, 2019

AMO Pharma Limited (“AMO Pharma”), today announced that Joe Horrigan, MD, AMO Pharma’s chief medical officer, presented an update on the company’s research targeting use of CNS therapies in the treatment of myotonic dystrophy (DM) during a full-day workshop on CNS involvement in DM held during the Myotonic Dystrophy Foundation Annual Conference

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today announced that it will present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment.

Epilepsy Foundation announced it is rolling out its Seizure Safe Schools initiative nationwide.

Varian (NYSE: VAR) today announced its ProBeam 360° proton therapy system is now available in a multi-room configuration.

DiamiR, a developer of innovative blood-based diagnostic tests for neurodegenerative and other diseases, announced today that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded DiamiR $345,000 in supplemental funding under the ongoing Small Business Innovation Research (SBIR) Phase IIB grant of $2,800,000 awarded in 2017.